GlobeNewswire Inc | Mar 19, 2021 07:45AM EDT

March 19, 2021

MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, CEO of Longeveron, will be presenting at the Q1 Virtual Investor Summit.

Event Q1 Investor SummitDate March 23-25, 2021Presentation March 24 @ 10:00 am ETLocation Small Cap Conference ZOOM Link

About The Investor SummitThe Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

About Longeveron

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Companys lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Companys mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

Contact:Crescendo Communications, LLCTel: 212-671-1020Email: lgvn@crescendo-ir.com

Investor Summit Contact:Brittney Blocker at brittney@investorsummitgroup.com

Wire Service ContactInvestorWire (IW) Los Angeles, Californiawww.InvestorWire.com212.418.1217 OfficeEditor@InvestorWire.com